Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): List JF;List JF; Habener JF
  • Source:
    American journal of physiology. Endocrinology and metabolism [Am J Physiol Endocrinol Metab] 2004 Jun; Vol. 286 (6), pp. E875-81.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: American Physiological Society Country of Publication: United States NLM ID: 100901226 Publication Model: Print Cited Medium: Print ISSN: 0193-1849 (Print) Linking ISSN: 01931849 NLM ISO Abbreviation: Am J Physiol Endocrinol Metab Subsets: MEDLINE
    • Publication Information:
      Original Publication: Bethesda, MD. : American Physiological Society
    • Subject Terms:
      Islets of Langerhans Transplantation*; Diabetes Mellitus, Type 1/*therapy ; Glucagon/*agonists ; Glucagon/*physiology ; Islets of Langerhans/*cytology ; Peptide Fragments/*agonists ; Peptide Fragments/*physiology ; Protein Precursors/*agonists ; Protein Precursors/*physiology; Animals ; Cell Division/physiology ; Diabetes Mellitus, Type 1/physiopathology ; Diabetes Mellitus, Type 2/physiopathology ; Diabetes Mellitus, Type 2/therapy ; Glucagon-Like Peptide 1 ; Humans
    • Abstract:
      Glucagon-like peptide 1 (GLP-1) is an intestine-derived insulinotropic hormone that stimulates glucose-dependent insulin production and secretion from pancreatic beta-cells. Other recognized actions of GLP-1 are to suppress glucagon secretion and hepatic glucose output, delay gastric emptying, reduce food intake, and promote glucose disposal in peripheral tissues. All of these actions are potentially beneficial for the treatment of type 2 diabetes mellitus. Several GLP-1 agonists are in clinical trials for the treatment of diabetes. More recently, GLP-1 agonists have been shown to stimulate the growth and differentiation of pancreatic beta-cells, as well as to exert cytoprotective, antiapoptotic effects on beta-cells. Recent evidence indicates that GLP-1 agonists act on receptors on pancreas-derived stem/progenitor cells to prompt their differentiation into beta-cells. These new findings suggest an approach to create beta-cells in vitro by expanding stem/progenitor cells and then to convert them into beta-cells by treatment with GLP-1. Thus GLP-1 may be a means by which to create beta-cells ex vivo for transplantation into patients with insulinopenic type 1 diabetes and severe forms of type 2 diabetes.
    • Number of References:
      78
    • Grant Information:
      R01 DK-30834 United States DK NIDDK NIH HHS; T32 DK-07028 United States DK NIDDK NIH HHS
    • Accession Number:
      0 (Peptide Fragments)
      0 (Protein Precursors)
      89750-14-1 (Glucagon-Like Peptide 1)
      9007-92-5 (Glucagon)
    • Publication Date:
      Date Created: 20040514 Date Completed: 20040625 Latest Revision: 20220408
    • Publication Date:
      20240829
    • Accession Number:
      10.1152/ajpendo.00007.2004
    • Accession Number:
      15140754